NKTX
Nkarta, Inc.
2.73
USD
This page is just a preview of the data found in TrendSpider’s full version
Nkarta, Inc. stock is up 18.48% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 December’s closed higher than November. In the last 6 Unusual Options Trades, there were 3 CALLs, 3 PUTs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 17 Oct 16:02 | 17 Nov, 2023 | 2.50 | 2117 | ||
| 17 Oct 16:15 | 17 Nov, 2023 | 2.50 | 2117 | ||
| 17 Oct 16:21 | 16 Feb, 2024 | 2.50 | 619 | ||
| 17 Oct 16:52 | 17 Nov, 2023 | 5.00 | 0 | ||
| 20 Oct 19:38 | 17 Nov, 2023 | 5.00 | 562 | ||
| 03 Nov 19:23 | 15 Dec, 2023 | 2.50 | 150 |
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens.
